Clinical Trial Update: Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma [NA]

View source ↗

Summary

The clinical trial evaluating a CAR-T therapy for relapsed or refractory multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CAR-T therapy (Chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Conditions: Relapsed or Refractory Multiple Myeloma | NA | Status: TERMINATED